Developer docs
API playgroundTry for free, no card

Search company profiles

OpenFold

Full company profile

uuid000mxh3

Namestring
OpenFold
Legal namestring
OpenFold Consortium
Websiteurl
openfold.io
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDavis, United States
HQ citystring
Davis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein structure prediction, open source AI, biomolecular modeling, drug discovery software, foundation models
Industry2 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Bioinformatics and AI-driven Protein Structure Prediction Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Consortium Membership Contributions
TypeLicensing Royalties
Description

OpenFold is a non-profit consortium. Organizations join as members contributing financially, through FTE (full-time equivalent) support, or in-kind resources (computing, data). These contributions sustain the consortium's operations and roadmap development. The project is hosted by the Open Molecular Software Foundation (OMSF), a 501(c)(3) non-profit.

openfold.io
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1OpenFold
Description

Core platform for high-accuracy protein folding predictions

openfold.io
+5 more records
Core offering1 text field

OpenFold develops and maintains open-source AI foundation models for predicting 3D biomolecular structures, including OpenFold (protein folding), OpenFold-Multimer (protein-protein complexes), OpenFold-SoloSeq (single-sequence prediction), and OpenFold3 (co-folding of proteins with nucleic acids and small molecules). All models, training pipelines, datasets, and pre-trained weights are released under the permissive Apache 2.0 license for both research and commercial use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 85% cost savings in computational infrastructure using AWS EC2 Capacity Blocks for ML and Spot Instances
+2 more records
Product overview1 text field

OpenFold is a non-profit AI research consortium developing open-source software tools for biology and drug discovery, hosted by the Open Molecular Software Foundation (OMSF). The core offering is OpenFold3, an open-source foundation model for predicting 3D structures of proteins, nucleic acids, and their complexes. The product portfolio includes OpenFold (core protein structure prediction), OpenFold-Multimer (protein-protein complexes), OpenFold-SoloSeq (single-sequence prediction without MSA), OpenFold-SmallMolecule (under development for ligand interactions), and OpenStability (protein stability prediction). Third-party tools built on OpenFold include AQAffinity (binding affinity prediction) and ApherisFold (privacy-preserving deployment). All models, training data, and code are released under permissive Apache 2.0 license, with inference code, training pipelines, and pre-trained weights available via GitHub and AWS Registry of Open Data.

Product and service5 records
1OpenFold
CategoryProtein structure prediction software
2OpenFold-Multimer
CategoryProtein-protein complex prediction software
3OpenFold-SoloSeq
CategorySingle-sequence protein structure prediction software
4OpenFold3
CategoryBiomolecular co-folding foundation model
5OpenStability
CategoryProtein stability prediction data and tooling
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership33 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Nxera Pharma joined OpenFold consortium to leverage state-of-the-art open-source structural prediction models and create synergies with its proprietary NxWave platform for GPCR target-focused drug discovery.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-28
Description

Continued collaboration on OpenFold3 release preview and AQAffinity model for rapid protein-ligand binding affinity prediction.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-07-16
Description

Apheris joined contributing privacy-preserving infrastructure enabling secure AI training and benchmarking on proprietary data without compromising confidentiality. Offers ApherisFold integration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-16
Description

Johnson & Johnson joined bringing deep expertise in AI and biomedical research to advance the consortium's goal of accelerating drug discovery.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-15
Description

Small-molecule therapeutics company joined as biotech member contributing to drug discovery applications.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-15
Description

Antibody discovery company joined contributing expertise in AI-powered antibody development for therapeutic applications.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-15
Description

Biotech company joined as consortium member supporting open AI infrastructure for biology.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-15
Description

Small-molecule therapeutics company joined contributing to drug discovery pipeline applications.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-15
Description

Biotech company joined contributing expertise in AI-powered therapeutic development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-18
Description

Led by Nobel Laureate David Baker. OpenFold launched research fellowship supporting graduate students and postdocs working on next-generation models for antibody-antigen design and structure prediction.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-08-13
Description

SandboxAQ contributed to OpenFold3 development enhancing protein-molecule structure prediction. Built AQAffinity on top of OpenFold3 for structure-free drug potency prediction under Apache 2.0 license.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-10
Description

Global pharmaceutical company joined as pharma consortium member contributing to open AI infrastructure for drug discovery.

13Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-15
Description

Bristol Myers Squibb joined as consortium member representing global pharma involvement in open AI infrastructure for biology and drug discovery.

openfold.io
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-15
Description

Novo Nordisk partnered on OpenFold3 development, collaborating with Columbia University and AWS to build cutting-edge open-source AI model for protein structure prediction. Achieved 85% cost savings using AWS EC2 Capacity Blocks.

15Astex
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-15
Description

Small molecule therapeutics company joined bringing expertise in fragment-based drug discovery and AI-driven design.

openfold.io
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-15
Description

Biopharmaceutical company joined contributing expertise in neuroscience and novel biologic therapies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-15
Description

Computational chemistry company joined contributing to AI-driven drug design methodologies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-15
Description

Quantum computing company joined bringing expertise in quantum computing applications for drug discovery.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-15
Description

Computational molecular design company joined; Woody Sherman, Chief Innovation Officer, serves as OpenFold Chairperson and Executive Committee Chair.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-02
Description

Prof. Gabriel Rocklin leads protein studies funded by OpenFold. Lab released mega-scale protein stability dataset advancing biomolecular AI research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-22
Description

Bayer joined as pharmaceutical member represented on Technical Advisory Council. Contributing to drug discovery applications of open AI infrastructure.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-11-22
Description

Dassault Systèmes joined in November 2022 to integrate AlphaFold AI models into its 3DEXPERIENCE platform for pharmaceutical research through BIOVIA brand.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-22
Description

Deep learning company joined contributing to AI-driven drug discovery and protein structure prediction.

24BaseCamp Research
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-22
Description

AI company joined contributing to biological data and protein analysis capabilities.

openfold.io
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-09-12
Description

NVIDIA joined as consortium member providing GPU computing support and expertise. OpenFold3 is deployable via NVIDIA NIM inference for optimized performance.

26UCB
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-12
Description

UCB joined as pharma consortium member contributing expertise in computational molecular design and CADD.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-12
Description

AI-powered drug discovery company (powered by Recursion) joined contributing computational biology expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-28
Description

Co-founding academic institution; Prof. Mohammed AlQuraishi leads development. Gustaf Ahdritz, PhD student in the lab, is lead developer of OpenFold.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-28
Description

Founding member and Executive Committee representation (CEO Alexandre Zanghellini). Protein design company using AI for enzyme and biosensor development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-28
Description

Founding member and Executive Committee representation (CEO Lucas Nivon). Provides protein modeling tools for biotech and pharma markets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-28
Description

Founding member and Vice Chairperson representation (Brian Weitzner). Cancer immunotherapy company focused on protein engineering.

Strategic tierCoreTypeTechnology or Integration
Description

AWS provides cloud computing infrastructure, EC2 Capacity Blocks for ML, and hosts training data on AWS Registry of Open Data through Open Data Sponsorship Program. Achieved 85% cost savings for OpenFold3 training using Spot Instances.

Strategic tierCoreTypeTechnology or Integration
Description

Supporting member providing DeepSpeed technology and research collaboration for distributed training optimization.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Creator of AlphaFold and AlphaFold3, the proprietary benchmark OpenFold3 is designed to match. Operates with vastly larger compute resources and feeds into Alphabet's Isomorphic Labs drug discovery pipeline.

2Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned commercial drug discovery company built on AlphaFold. Competes for the same pharma partnerships OpenFold targets and represents the commercial endpoint of the closed-source alternative.

TypeEmerging player
Description

AI protein design company building frontier foundation models for biology (ESM3). Comparable to OpenFold in modality (protein language/structure models) but pursuing a venture-backed, partially closed commercialization path.

TypeEmerging player
Description

AI protein design company using large language models to design novel proteins. Competes with OpenFold in the protein design space and serves similar biotech and pharma customers with proprietary offerings.

TypeEmerging player
Description

AI-driven protein engineering company focused on designing improved proteins for therapeutics and industrial applications. Comparable technology stack and customer base to OpenFold's biotech/biopharma users.

TypeEmerging player
Description

AI foundation models for molecular structure prediction and design, with explicit focus on protein-ligand co-folding. Direct competitor to OpenFold3 in biomolecular co-folding capabilities.

TypeBroad incumbent
Description

Computational chemistry and drug discovery platform combining physics-based simulation with AI/ML. Sells to the same large pharma and biotech customers OpenFold consortium members represent.

TypeBroad incumbent
Description

AI-driven drug discovery company using high-throughput biology and machine learning; operates Valence Labs as its AI research arm (an OpenFold consortium member). Competes for the same pharma AI partnerships.

TypeEmerging player
Description

AI-driven drug discovery company with proprietary molecular AI models for structure prediction and protein-ligand binding. Comparable in capability and target customers to OpenFold's drug discovery focus.

TypeBroad incumbent
Description

AI-driven drug discovery company operating its own foundation models for biology and chemistry. Competes in the same AI-for-drug-discovery category and serves overlapping pharma customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OpenFold

Bioinformatics and AI-driven Protein Structure Prediction Softwareopenfold.io

OpenFold firmographics

Firmographics
Name
OpenFold
Legal name
OpenFold Consortium
Website
https://openfold.io
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

OpenFold industry classification

Industry
Product category
Bioinformatics and AI-driven Protein Structure Prediction Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Protein structure prediction
  • Open source AI
  • Biomolecular modeling
  • Drug discovery software
  • Foundation models

Where OpenFold is headquartered

Location

Headquarters

HQ city
Davis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OpenFold business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Operations

Revenue model

  1. Consortium Membership Contributions: OpenFold is a non-profit consortium. Organizations join as members contributing financially, through FTE (full-time equivalent) support, or in-kind resources (computing, data). These contributions sustain the consortium's operations and roadmap development. The project is hosted by the Open Molecular Software Foundation (OMSF), a 501(c)(3) non-profit.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

OpenFold product offering

Product offering

Core offering

OpenFold develops and maintains open-source AI foundation models for predicting 3D biomolecular structures, including OpenFold (protein folding), OpenFold-Multimer (protein-protein complexes), OpenFold-SoloSeq (single-sequence prediction), and OpenFold3 (co-folding of proteins with nucleic acids and small molecules). All models, training pipelines, datasets, and pre-trained weights are released under the permissive Apache 2.0 license for both research and commercial use.

Product overview

OpenFold is a non-profit AI research consortium developing open-source software tools for biology and drug discovery, hosted by the Open Molecular Software Foundation (OMSF). The core offering is OpenFold3, an open-source foundation model for predicting 3D structures of proteins, nucleic acids, and their complexes. The product portfolio includes OpenFold (core protein structure prediction), OpenFold-Multimer (protein-protein complexes), OpenFold-SoloSeq (single-sequence prediction without MSA), OpenFold-SmallMolecule (under development for ligand interactions), and OpenStability (protein stability prediction). Third-party tools built on OpenFold include AQAffinity (binding affinity prediction) and ApherisFold (privacy-preserving deployment). All models, training data, and code are released under permissive Apache 2.0 license, with inference code, training pipelines, and pre-trained weights available via GitHub and AWS Registry of Open Data.

Differentiator

Problem solved

Functional benefit

Brands

  • OpenFold: Core platform for high-accuracy protein folding predictions
  • OpenFold-Multimer
  • OpenFold-SoloSeq
  • OpenFold3
  • OpenFold-SmallMolecule
  • OpenStability

Products and services

  • OpenFold
  • OpenFold-Multimer
  • OpenFold-SoloSeq
  • OpenFold3
  • OpenStability

Quantifiable outcome

  • 85% cost savings in computational infrastructure using AWS EC2 Capacity Blocks for ML and Spot Instances
  • +2 more outcomes

Companies that use OpenFold

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

OpenFold technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

OpenFold partnerships and signals

Strategic signal

Partnerships

33 partnerships are on record, tiered core and minor.

  • Nxera PharmacoreStrategic or Co-development Partner · 10 June 2026Nxera Pharma joined OpenFold consortium to leverage state-of-the-art open-source structural prediction models and create synergies with its proprietary NxWave platform for GPCR target-focused drug discovery.
  • SandboxAQcoreTechnology or Integration · 28 October 2025Continued collaboration on OpenFold3 release preview and AQAffinity model for rapid protein-ligand binding affinity prediction.
  • ApheriscoreTechnology or Integration · 16 July 2025Apheris joined contributing privacy-preserving infrastructure enabling secure AI training and benchmarking on proprietary data without compromising confidentiality. Offers ApherisFold integration.
  • Johnson & JohnsoncoreStrategic or Co-development Partner · 16 July 2025Johnson & Johnson joined bringing deep expertise in AI and biomedical research to advance the consortium's goal of accelerating drug discovery.
  • Structure TherapeuticsminorStrategic or Co-development Partner · 15 April 2025Small-molecule therapeutics company joined as biotech member contributing to drug discovery applications.
  • COGNANOminorStrategic or Co-development Partner · 15 April 2025Antibody discovery company joined contributing expertise in AI-powered antibody development for therapeutic applications.
  • TamarindminorStrategic or Co-development Partner · 15 April 2025Biotech company joined as consortium member supporting open AI infrastructure for biology.
  • Unnatural ProductsminorStrategic or Co-development Partner · 15 April 2025Small-molecule therapeutics company joined contributing to drug discovery pipeline applications.
  • VisterraminorStrategic or Co-development Partner · 15 April 2025Biotech company joined contributing expertise in AI-powered therapeutic development.
  • University of Washington (Institute for Protein Design)coreStrategic or Co-development Partner · 18 March 2025Led by Nobel Laureate David Baker. OpenFold launched research fellowship supporting graduate students and postdocs working on next-generation models for antibody-antigen design and structure prediction.
  • SandboxAQcoreTechnology or Integration · 13 August 2024SandboxAQ contributed to OpenFold3 development enhancing protein-molecule structure prediction. Built AQAffinity on top of OpenFold3 for structure-free drug potency prediction under Apache 2.0 license.
  • RochecoreStrategic or Co-development Partner · 10 June 2024Global pharmaceutical company joined as pharma consortium member contributing to open AI infrastructure for drug discovery.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 15 April 2024Bristol Myers Squibb joined as consortium member representing global pharma involvement in open AI infrastructure for biology and drug discovery.
  • Novo NordiskcoreStrategic or Co-development Partner · 15 April 2024Novo Nordisk partnered on OpenFold3 development, collaborating with Columbia University and AWS to build cutting-edge open-source AI model for protein structure prediction. Achieved 85% cost savings using AWS EC2 Capacity Blocks.
  • AstexminorStrategic or Co-development Partner · 15 April 2024Small molecule therapeutics company joined bringing expertise in fragment-based drug discovery and AI-driven design.
  • BiogenminorStrategic or Co-development Partner · 15 April 2024Biopharmaceutical company joined contributing expertise in neuroscience and novel biologic therapies.
  • CongruenceminorStrategic or Co-development Partner · 15 April 2024Computational chemistry company joined contributing to AI-driven drug design methodologies.
  • Polaris QuantumminorStrategic or Co-development Partner · 15 April 2024Quantum computing company joined bringing expertise in quantum computing applications for drug discovery.
  • PsivantminorStrategic or Co-development Partner · 15 April 2024Computational molecular design company joined; Woody Sherman, Chief Innovation Officer, serves as OpenFold Chairperson and Executive Committee Chair.
  • Northwestern University (Rocklin Lab)coreStrategic or Co-development Partner · 2 October 2023Prof. Gabriel Rocklin leads protein studies funded by OpenFold. Lab released mega-scale protein stability dataset advancing biomolecular AI research.
  • BayercoreStrategic or Co-development Partner · 22 November 2022Bayer joined as pharmaceutical member represented on Technical Advisory Council. Contributing to drug discovery applications of open AI infrastructure.
  • Dassault Systèmes (BIOVIA)coreTechnology or Integration · 22 November 2022Dassault Systèmes joined in November 2022 to integrate AlphaFold AI models into its 3DEXPERIENCE platform for pharmaceutical research through BIOVIA brand.
  • CHARM TherapeuticsminorStrategic or Co-development Partner · 22 November 2022Deep learning company joined contributing to AI-driven drug discovery and protein structure prediction.
  • BaseCamp ResearchminorStrategic or Co-development Partner · 22 November 2022AI company joined contributing to biological data and protein analysis capabilities.
  • NVIDIAcoreTechnology or Integration · 12 September 2022NVIDIA joined as consortium member providing GPU computing support and expertise. OpenFold3 is deployable via NVIDIA NIM inference for optimized performance.
  • UCBcoreStrategic or Co-development Partner · 12 September 2022UCB joined as pharma consortium member contributing expertise in computational molecular design and CADD.
  • Valence Labs (Recursion)minorStrategic or Co-development Partner · 12 September 2022AI-powered drug discovery company (powered by Recursion) joined contributing computational biology expertise.
  • Columbia University (AlQuraishi Lab)coreStrategic or Co-development Partner · 28 June 2022Co-founding academic institution; Prof. Mohammed AlQuraishi leads development. Gustaf Ahdritz, PhD student in the lab, is lead developer of OpenFold.
  • ArzedacoreStrategic or Co-development Partner · 28 June 2022Founding member and Executive Committee representation (CEO Alexandre Zanghellini). Protein design company using AI for enzyme and biosensor development.
  • Cyrus BiotechnologycoreStrategic or Co-development Partner · 28 June 2022Founding member and Executive Committee representation (CEO Lucas Nivon). Provides protein modeling tools for biotech and pharma markets.
  • Outpace BiocoreStrategic or Co-development Partner · 28 June 2022Founding member and Vice Chairperson representation (Brian Weitzner). Cancer immunotherapy company focused on protein engineering.
  • Amazon Web Services (AWS)coreTechnology or IntegrationAWS provides cloud computing infrastructure, EC2 Capacity Blocks for ML, and hosts training data on AWS Registry of Open Data through Open Data Sponsorship Program. Achieved 85% cost savings for OpenFold3 training using Spot Instances.
  • MicrosoftcoreTechnology or IntegrationSupporting member providing DeepSpeed technology and research collaboration for distributed training optimization.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

OpenFold competitors and assessment

Company assessment

Broad incumbents

  • Google DeepMind (AlphaFold): Creator of AlphaFold and AlphaFold3, the proprietary benchmark OpenFold3 is designed to match. Operates with vastly larger compute resources and feeds into Alphabet's Isomorphic Labs drug discovery pipeline.
  • Isomorphic Labs: Alphabet-owned commercial drug discovery company built on AlphaFold. Competes for the same pharma partnerships OpenFold targets and represents the commercial endpoint of the closed-source alternative.
  • Schrödinger: Computational chemistry and drug discovery platform combining physics-based simulation with AI/ML. Sells to the same large pharma and biotech customers OpenFold consortium members represent.
  • Recursion: AI-driven drug discovery company using high-throughput biology and machine learning; operates Valence Labs as its AI research arm (an OpenFold consortium member). Competes for the same pharma AI partnerships.
  • Insilico Medicine: AI-driven drug discovery company operating its own foundation models for biology and chemistry. Competes in the same AI-for-drug-discovery category and serves overlapping pharma customers.

Emerging players

  • EvolutionaryScale: AI protein design company building frontier foundation models for biology (ESM3). Comparable to OpenFold in modality (protein language/structure models) but pursuing a venture-backed, partially closed commercialization path.
  • Profluent Bio: AI protein design company using large language models to design novel proteins. Competes with OpenFold in the protein design space and serves similar biotech and pharma customers with proprietary offerings.
  • Cradle Bio: AI-driven protein engineering company focused on designing improved proteins for therapeutics and industrial applications. Comparable technology stack and customer base to OpenFold's biotech/biopharma users.
  • Chai Discovery: AI foundation models for molecular structure prediction and design, with explicit focus on protein-ligand co-folding. Direct competitor to OpenFold3 in biomolecular co-folding capabilities.
  • Genesis Therapeutics: AI-driven drug discovery company with proprietary molecular AI models for structure prediction and protein-ligand binding. Comparable in capability and target customers to OpenFold's drug discovery focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

OpenFold social profiles

Digital presence

OpenFold financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OpenFold leadership team

Management profile

Number of profiles

Profiles14 records

OpenFold funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OpenFold M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OpenFold

What does OpenFold do?

OpenFold develops and maintains open-source AI foundation models for predicting 3D biomolecular structures, including OpenFold (protein folding), OpenFold-Multimer (protein-protein complexes), OpenFold-SoloSeq (single-sequence prediction), and OpenFold3 (co-folding of proteins with nucleic acids and small molecules). All models, training pipelines, datasets, and pre-trained weights are released under the permissive Apache 2.0 license for both research and commercial use.

Is OpenFold a public or private company?

OpenFold is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was OpenFold founded?

OpenFold was founded in 2021. It employs 1 to 10 people.

Where is OpenFold based?

OpenFold is headquartered in Davis, United States, in the North America region.

How does OpenFold make money?

One revenue line is on record: consortium Membership Contributions.

Who are OpenFold's main competitors?

Broad incumbents on record are Google DeepMind (AlphaFold), Isomorphic Labs, Schrödinger, Recursion and Insilico Medicine. Emerging players are EvolutionaryScale, Profluent Bio, Cradle Bio, Chai Discovery and Genesis Therapeutics.

Does OpenFold have an API?

No public API is recorded for OpenFold.

What industry is OpenFold in?

OpenFold's product category is Bioinformatics and AI-driven Protein Structure Prediction Software. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug DiscoveryNxera Pharma announced it has joined OpenFold, a non-profit AI research consortium that develops open-source AI software tools for biology and drug discovery. Through this membership, Nxera aims to leverage state-of-the-art open-source structural prediction models and create synergies with its proprietary NxWave™ platform to accelerate GPCR target-focused drug discovery. The consortium includes major pharmaceutical companies such as Bristol Myers Squibb, Novo Nordisk, Bayer, and Roche, as well as technology companies including Amazon Web Services, Microsoft, and NVIDIA as supporting members.BioSpaceNxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug DiscoveryNxera Pharma joined OpenFold, a non-profit AI research consortium, alongside major pharma and tech firms. The company will use OpenFold's open-source tools to accelerate GPCR drug discovery, with no proprietary data contribution required. Nxera aims to improve R&D productivity and advance toward its 2030 vision.YahooNxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug DiscoveryNxera Pharma joined OpenFold, a non-profit AI research consortium, to accelerate AI-enabled drug discovery. The company will use OpenFold's open-source tools and evaluate them with its NxWave GPCR platform, without contributing proprietary data. Nxera aims to improve R&D productivity and advance from target to clinical development.Business Wire BlogOpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug DiscoveryThe OpenFold Consortium, an open-source AI initiative for biology and drug discovery, announced the addition of eleven new members to its network. The new participants include Absci, Adaptive Biotechnologies, Benchling, Chemical Computing Group, Daiichi Sankyo, Flagship Pioneering, Kiin Bio, Nanome, Nxera, Pledge Tx, and Superluminal. This expansion aims to advance the development of shared, open-source foundation models and software infrastructure for biological research.Timmerman ReportBeyond Language: Why Drug Discovery Needs a Different Kind of AIThis is an opinion piece by Woody Sherman, chief innovation officer of PsiThera and Chair of the OpenFold Consortium Executive Committee, arguing that current language-based AI systems (such as ChatGPT, Claude, and Gemini) are insufficient for drug discovery because they cannot reliably predict the physical properties of molecules in biological systems. The author proposes "Physical AI" as a complementary approach that can predict molecular behavior including binding, solubility, metabolism, and toxicity, and advocates for investors and managers to evaluate AI in drug discovery based on scientific leverage rather than operational efficiency. Sherman identifies co-folding and biomolecular structure prediction as promising areas where the field has made significant progress, citing the 2024 Nobel Prize in Chemistry.AmdOpenFold3 Meets AMD Instinct™ GPUs: Unlocking Scalable, High-Throughput Structural BiologyAMD Instinct GPUs accelerate OpenFold3 inference, achieving up to 45.5% faster performance on MI355X versus NVIDIA B200 at sequence length 5,000. The GPUs also support longer sequences, with MI355X reaching 6,000 tokens versus B200's 5,000, enabling larger biomolecular modeling.Business Wire BlogOpen Molecular Software Foundation’s OpenFold Consortium Launches Research Fellowship at the University of Washington’s Institute for Protein DesignThe Open Molecular Software Foundation (OMSF) announced a new research fellowship between the OpenFold Consortium and the University of Washington's Institute for Protein Design (IPD), supporting graduate students and postdoctoral scholars in the Baker Lab with a focus on developing AI models for antibody-antigen design and structure prediction. All code and finished models from the collaboration will be publicly released under permissive licenses for use by researchers and companies worldwide. The initiative is framed as building open-source AI infrastructure for drug discovery, with Nobel Laureate David Baker leading the IPD as its Director.Business Wire BlogOpenFold Consortium Announces Major OpenFold3 Update and Public Release of Training Data for Reproducible Biomolecular AIThe OpenFold Consortium announced a major update to OpenFold3, an open-source deep learning system for cofolding that predicts 3D structures of biomolecular complexes, along with the public release of training datasets, model weights, and full-stack tooling via the Registry of Open Data on AWS. The release enables independent reproduction of results, benchmarking, and model fine-tuning under permissive licenses, with updated benchmarks reportedly showing competitive performance versus AlphaFold3 across multiple modalities. The consortium, hosted as a project of the Open Molecular Software Foundation, aims to accelerate adoption and innovation in biomolecular AI for drug discovery by providing transparent, auditable open infrastructure to the global scientific community.MorningstarOpenFold Consortium Announces Major OpenFold3 Update and Public Release of Training Data for Reproducible Biomolecular AIThe OpenFold Consortium announced a major OpenFold3 update with the public release of full training datasets, model weights, training and inference code, and evaluation scripts for reproducible biomolecular AI, made available via AWS Registry of Open Data. The update includes competitive benchmarks showing OpenFold3 performing comparably to AlphaFold3 across most evaluated modalities, along with a new portal, onboarding documentation, and community support channels for technical Q&A. The consortium identified antibody-antigen complex prediction as a major 2026 priority for improvement, positioning OpenFold3 as a foundation for community-driven advancement in drug discovery and molecular design.UnderstandingaiAn unlikely ally for open-source protein-folding models: Big PharmaOpenFold, an academic project co-founded by Columbia professor Mohammed AlQuraishi in 2021, has secured approximately $17 million in donated computing power from pharmaceutical companies to replicate and openly release protein-folding AI models originally developed by Google DeepMind's AlphaFold. The project, which releases all models, training data, and source code publicly while giving pharma funders input on research priorities and early access, represents an unusual collaboration model that aligns academic open-science goals with industry need for non-proprietary AI tools. OpenFold is currently working to replicate AlphaFold 3, which Google DeepMind released with significant access restrictions through its commercial subsidiary Isomorphic Labs.